Medicago, a Canadian vaccine manufacturer (yes! we have one 🇨🇦!) is expanding its Phase 3 trial in Brazil.
CureVac says that they expect to get data from their Phase 3 trial in late April or May and is hoping for EU regulatory approval in June. CureVac is interesting because:
- It’s mRNA with a 2-proline modification.
- It multivalent, meaning that it encodes multiple different variants.
The US Army (!) is developing a vaccine which is multivalent, with a bunch of different spikes around a central hub.